The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2

Maihulan Maimaiti, Shinichi Sakamoto, Masahiro Sugiura, Manato Kanesaka, Ayumi Fujimoto, Keisuke Matsusaka, Minhui Xu, Keisuke Ando, Shinpei Saito, Ken Wakai, Yusuke Imamura, Keiichi Nakayama, Yoshikatsu Kanai, Atsushi Kaneda, Yuzuru Ikehara, Jun Ichiro Ikeda, Naohiko Anzai, Tomohiko Ichikawa

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


The 4F2 cell-surface antigen heavy chain (4F2hc) forms a heterodimeric complex with L-type amino acid transporter 1 (LAT1) and transports large neutral essential amino acids. However, in contrast to the traditional role of LAT1 in various cancers, the role of 4F2hc has largely remained unknown. The role of 4F2hc in prostate cancer was studied. Treatment of C4-2 cells with si4F2hc was found to suppress cellular growth, migratory and invasive abilities, with this effect occurring through the cell cycle, with a significant decrease in S phase and a significant increase in G0/G1 phase, suggesting cell cycle arrest. In addition, it was proven by RNA seq that the key to 4F2hc’s impact on cancer is SKP2. si4F2hc upregulates the protein expression of cyclin-dependent kinase inhibitors (P21cip1, P27kip1) through the downstream target SKP2. Furthermore, the expression of 4F2hc and LAT1 in prostate cancer cells suggests the importance of 4F2hc. Multivariate analysis showed that high 4F2hc expression was an independent prognostic factor for progression-free survival (HR 11.54, p = 0.0357). High 4F2hc was related to the clinical tumour stage (p = 0.0255) and Gleason score (p = 0.0035). Collectively, 4F2hc contributed significantly to prostate cancer (PC) progression. 4F2hc may be a novel marker and therapeutic target in PC.

Original languageEnglish
Article number11478
JournalScientific reports
Issue number1
Publication statusPublished - Dec 2021

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'The heavy chain of 4F2 antigen promote prostate cancer progression via SKP-2'. Together they form a unique fingerprint.

Cite this